文传商讯
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Sy
2026-10-29 17:49:50
Galderma’s Relfydess (relabotulinumtoxinA) Receives Approval in China for Frown Lines
2026-10-29 17:49:50
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically
2026-10-27 04:14:22



